The observational study will be carried out in two stages. At the first stage, the efficacy and safety of Aprotinin intravenous infusion as add-on therapy to the standard of care will be studied. At the second stage, two groups will be included: the first group will be the inhaled Aprotinin add-on therapy, the second group will be intravenous Aprotinin in combination with Favipiravir.

开始日期2020-06-11

申办/合作机构

Aviron LLC

100 项与 Aprotinin(Aviron LLC) 相关的临床结果

登录后查看更多信息

100 项与 Aprotinin(Aviron LLC) 相关的转化医学

登录后查看更多信息

100 项与 Aprotinin(Aviron LLC) 相关的专利（医药）

登录后查看更多信息

3,992

项与 Aprotinin(Aviron LLC) 相关的文献（医药）

2024-12-31·Scandinavian Cardiovascular Journal

In Nordic countries 30-day mortality rate is half that estimated with EuroSCORE II in high-risk adult patients given aprotinin and undergoing mainly complex cardiac procedures

Article

作者: Nyström, Fredrik ; Hammas, Bengt ; Parviainen, Maria ; van der Linden, Jan ; Cunha-Goncalves, Doris ; Wahba, Alexander ; Hiippala, Seppo ; Fux, Thomas ; Toivonen, Jenni M ; Rutanen, Juha ; Kaakinen, Timo

Objectives. To describe current on- (isolated coronary arterty bypass grafting, iCABG) and off-label (non-iCABG) use of aprotinin and associated safety endpoints in adult patients undergoing high-risk cardiac surgery in Nordic countries. Design. Data come from 10 cardiac surgery centres in Finland, Norway and Sweden participating in the European Nordic aprotinin patient registry (NAPaR). Results. 486 patients were given aprotinin between 2016 and 2020. 59 patients (12.1%) underwent iCABG and 427 (87.9%) non-iCABG, including surgery for aortic dissection (16.7%) and endocarditis (36.0%). 89.9% were administered a full aprotinin dosage and 37.0% were re-sternotomies. Dual antiplatelet treatment affected 72.9% of iCABG and 7.0% of non-iCABG patients. 0.6% of patients had anaphylactic reactions associated with aprotinin. 6.4% (95 CI% 4.2%-8.6%) of patients were reoperated for bleeding. Rate of postoperative thromboembolic events, day 1 rise in creatinine >44μmol/L and new dialysis for any reason was 4.7% (95%CI 2.8%-6.6%), 16.7% (95%CI 13.4%-20.0%) and 14.0% (95%CI 10.9%-17.1%), respectively. In-hospital mortality and 30-day mortality was 4.9% (95%CI 2.8%-6.9%) and 6.3% (95%CI 3.7%-7.8%) in all patients versus mean EuroSCORE II 11.4% (95%CI 8.4%-14.0%, p < .01). 30-day mortality in patients undergoing surgery for aortic dissection and endocarditis was 6.2% (95%CI 0.9%-11.4%) and 6.3% (95%CI 2.7%-9.9%) versus mean EuroSCORE II 13.2% (95%CI 6.1%-21.0%, p = .11) and 14.5% (95%CI 12.1%-16.8%, p = .01), respectively. Conclusions. NAPaR data from Nordic countries suggest a favourable safety profile of aprotinin in adult cardiac surgery.

2024-11-01·Annales Pharmaceutiques Françaises

Cost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass

Article

作者: Puntous, Maryse ; Ong, Nathalie ; Ramaroson, Hanta ; Huynh, Clémence ; Xuereb, Fabien ; Gallo, Eloise ; Ouattara, Alexandre ; Trin, Kilian ; Crubezy, Isabelle ; Perino, Justine

OBJECTIVESAn increased risk of mortality and postoperative side effects led to aprotinin (Trasylol®) withdrawal from the market in 2008, but since 2018 aprotinin has again been used in France. The French retrospective multicentre APACHE study (AProtinin versus tranexamic Acid in Cardiac surgery patients with High-risk for Excessive bleeding) compared the efficacy of tranexamic acid versus half-dose aprotinin. The aim of this study, ancillary to the APACHE study, is to carry out a medico-economic analysis of the use of these two antifibrinolytics on an APACHE subpopulation.METHODSEconomic data on reimbursement by the French health insurance system were extracted from the program for the data processing of medical information, and quantitative data on the cost of healthcare products were obtained from the hospital pharmacy software.RESULTSThe main analysis of costs for the population shows that the global valuation was not significantly different between the two treatment groups (P=0.60), but the costs of blood products included in the related hospital stay group (Groupe Homogène de séjour [GHS]) (whole blood, platelets and plasma) were higher for the tranexamic acid group (P=0.007). In a sub-analysis of patients alive at discharge, the costs of blood products in addition to GHS (blood-derived medicines) and the costs of blood products in the GHS were higher for the tranexamic acid group (P=0.04 and 0.001, respectively).CONCLUSIONSThe additional cost of aprotinin at the time of purchase is offset by the additional costs of blood products in the tranexamic acid group.

2024-05-01·Transfusion

Lack of efficacy of aprotinin over tranexamic acid in type A aortic dissection repair

Article

作者: Sitaranjan, Daniel ; Falter, Florian ; Fazmin, Ibrahim Talal ; De Silva, Ravi ; Aston, Daniel ; Ali, Jason ; Muir, Martin ; Reidy, Bryan

AbstractBackgroundThe role of aprotinin in modern cardiac surgery is not well defined. While licensed for use in isolated coronary artery bypass grafting it is more commonly used for cases deemed to be at an increased risk of bleeding. The relative efficacy, and safety profile, of aprotinin as compared to other antifibrinolytics in these high‐risk cases is uncertain.Study Design and MethodsA retrospective observational study with propensity matching to determine whether aprotinin versus tranexamic acid reduced bleeding or transfusion requirements in patients presenting for surgical repair of type A aortic dissection (TAD).ResultsBetween 2016 and 2022, 250 patients presented for repair of TAD. A total of 231 patients were included in the final analysis. Bleeding and transfusion were similar between both groups in both propensity matched and unmatched cohorts. Compared to tranexamic acid, aprotinin use did not reduce transfusion requirements for any product. Rates of bleeding in the first 12 h, return to theater and return to intensive care unit with an open packed chest were similar between groups. There was no difference in rates of renal failure, stroke, or death.ConclusionAprotinin did not reduce the risk of bleeding or transfusion requirements in patients undergoing repair of type A aortic dissections. Efficacy of aprotinin may vary depending on the type of surgery performed and the underlying pathology.

100 项与 Aprotinin(Aviron LLC) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02971	-	-	-

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2004	N/A	uPA \| tPA	-	Aprotinin treatment	蓋網顧齋範餘鑰觸鑰襯(淵製艱醖襯艱獵鹹觸醖) = plasminogen-dependent casein hydrolysis was restricted to the leading edge of migrating epithelial cells in no-aprotinin and aprotinin treated corneal tissue after PRK. The hydrolysis was inhibited by a polyclonal anti-uPA antibody, amiloride, but not with polyclonal anti-tPA antibody. No plasminogen-independent lysis was observed. 鹹廠淵壓觸餘廠蓋餘餘 (築衊淵夢廠淵遞鏇衊淵 ) 更多	-	2004-05-01
				No Aprotinin treatment